Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Renal Cell 5von Hippel-Lindau Disease 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Hemangioblastoma 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1

Interventions

Radiotherapy 7Brachytherapy 6Surveys and Questionnaires 4Magnetic Resonance Spectroscopy 4durvalumab 3Radiosurgery 3Methods 3tremelimumab 2aldesleukin 2Topotecan 2Radiation 2Palliative Care 2Paclitaxel 2Immunoglobulin G 2Gemcitabine 2Early Intervention, Educational 2Disulfides 2Dehydroepiandrosterone 2Counseling 2Capecitabine 2Bevacizumab 2Behavior Therapy 2Adoptive Transfer 2zimberelimab 1temsirolimus 1talazoparib 1rocakinogene sifuplasmid 1liposomal doxorubicin 1fludarabine phosphate 1dostarlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Vaginal Neoplasms × belzutifan × Clear all
NCT06677190 2025-11-05

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

Dana-Farber Cancer Institute

Phase 2 Recruiting
32 enrolled
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡